Cue Biopharma Statistics

Total Valuation

Cue Biopharma has a market cap or net worth of $43.21 million. The enterprise value is $28.97 million.

Market Cap	43.21M
Enterprise Value	28.97M

Important Dates

The last earnings date was Wednesday, November 12, 2025, after market close.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Cue Biopharma has 78.74 million shares outstanding. The number of shares has increased by 74.30% in one year.

Current Share Class	78.74M
Shares Outstanding	78.74M
Shares Change (YoY)	+74.30%
Shares Change (QoQ)	+5.67%
Owned by Insiders (%)	0.34%
Owned by Institutions (%)	24.33%
Float	78.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.67
Forward PS	2.62
PB Ratio	3.22
P/TBV Ratio	3.26
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.47.

Current Ratio	1.66
Quick Ratio	1.46
Debt / Equity	0.47
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-83.02

Financial Efficiency

Return on equity (ROE) is -195.19% and return on invested capital (ROIC) is -87.73%.

Return on Equity (ROE)	-195.19%
Return on Assets (ROA)	-62.31%
Return on Invested Capital (ROIC)	-87.73%
Return on Capital Employed (ROCE)	-236.40%
Revenue Per Employee	$173,171
Profits Per Employee	-$919,098
Employee Count	41
Asset Turnover	0.19
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.72% in the last 52 weeks. The beta is 1.40, so Cue Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.40
52-Week Price Change	-46.72%
50-Day Moving Average	0.70
200-Day Moving Average	0.78
Relative Strength Index (RSI)	34.29
Average Volume (20 Days)	361,225

Short Selling Information

The latest short interest is 509,612, so 0.65% of the outstanding shares have been sold short.

Short Interest	509,612
Short Previous Month	365,072
Short % of Shares Out	0.65%
Short % of Float	0.65%
Short Ratio (days to cover)	1.46

Income Statement

In the last 12 months, Cue Biopharma had revenue of $7.10 million and -$37.68 million in losses. Loss per share was -$0.44.

Revenue	7.10M
Gross Profit	-28.33M
Operating Income	-38.11M
Pretax Income	-37.68M
Net Income	-37.68M
EBITDA	-37.73M
EBIT	-38.11M
Loss Per Share	-$0.44

Full Income Statement

Balance Sheet

The company has $20.42 million in cash and $6.17 million in debt, giving a net cash position of $14.25 million or $0.18 per share.

Cash & Cash Equivalents	20.42M
Total Debt	6.17M
Net Cash	14.25M
Net Cash Per Share	$0.18
Equity (Book Value)	13.25M
Book Value Per Share	0.17
Working Capital	10.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$29.64 million and capital expenditures -$179,000, giving a free cash flow of -$29.82 million.

Operating Cash Flow	-29.64M
Capital Expenditures	-179,000
Free Cash Flow	-29.82M
FCF Per Share	-$0.38

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-536.73%
Pretax Margin	-530.75%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cue Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-74.30%
Shareholder Yield	-74.30%
Earnings Yield	-87.21%
FCF Yield	-69.01%

Analyst Forecast

The average price target for Cue Biopharma is $3.00, which is 446.65% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.00
Price Target Difference	446.65%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	-30.91%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cue Biopharma has an Altman Z-Score of -17.56 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-17.56
Piotroski F-Score	2